Frances Arnold Receives Grant to Innovate Therapeutics for Angelman Syndrome
In a groundbreaking development, Dr. Frances Arnold, who was awarded the Nobel Prize in Chemistry in 2018, is set to make strides in targeting Angelman Syndrome through a newly funded project. The Foundation for Angelman Syndrome Therapeutics (FAST) has granted Dr. Arnold a two-year funding opportunity to innovate molecular tools for RNA-targeted therapeutics aimed at this rare neurogenetic condition.
Angelman Syndrome is characterized by the loss of function of the UBE3A gene, primarily inherited from the mother. Individuals with this condition face multiple challenges including developmental delays, motor difficulties, and speech impairments. Given the complexities surrounding the disorder, the implications of effective RNA-targeted therapies are profound; they promise not only to alleviate symptoms but also to enhance overall development and quality of life for affected individuals.
Dr. Arnold's project will harness the power of directed evolution—a technique she developed—to engineer enzymes that create new nucleoside analogs. These synthetic molecules have the potential to resist breakdown in the body, which is crucial for improving the efficacy of RNA therapeutics. The process is not merely academic; it represents a significant leap in practical applications that could lead to new therapies for Angelman Syndrome.
In this particular project, the aim is to produce nucleoside analogs that will effectively target the UBE3A antisense transcript (UBE3A-ATS). This approach has the potential not only to drive forward existing research but to provide a foundation for future treatments that might prove beneficial to patients. Dr. Arnold commented on the excitement of merging biochemistry and technological innovation, reflecting on the unprecedented opportunities these new building blocks bring for RNA therapeutics targeting Angelman Syndrome.
Despite their promise, nucleoside analogs present manufacturing challenges that have limited widespread use in the therapeutic landscape. However, by combining directed evolution and machine learning techniques, Dr. Arnold’s lab is aiming to overcome these obstacles to manufacture these critical molecules more efficiently. The first phase of this research will likely center around generating new therapeutic candidates that boast enhanced physical properties, ultimately leading to the discovery of more effective treatments.
FAST's initiative supports the second pillar of its Angelman syndrome drug development pipeline, concentrating on therapies that focus on the expression of the paternal UBE3A gene that remains dormant in patients. If this research yields promising candidates, experimental testing will be conducted with collaborators involved in the Angelman Syndrome research network, using AS neuronal cell lines and animal models.
Dr. Allyson Berent, Chief Science Officer of FAST, emphasized the importance of scientific progression in moving forward with Angelman Syndrome drug development. This grant facilitates collaboration with one of the foremost experts in the field, potentially expediting the transition from promising research to tangible therapies.
Supporting this endeavor is Maddie's Mission Foundation in partnership with the Shaw Family, a group dedicated to improving the lives of those with Angelman syndrome and other rare neurological disorders. Alana Newhouse, President of FAST, affirmed the significance of investment into research that blends top-tier scientific expertise with a focus on real-world applications. It is efforts like these that will not only create pathways for potential therapies today but will also ensure that future innovations are explored and utilized effectively.
The investment from FAST highlights its broader mission to fund the essential tools and research needed to transition from scientific opportunity to practical therapeutic solutions for individuals living with Angelman Syndrome. As the project progresses, there is a renewed hope for families affected by this condition, representing a promising avenue for advancing medical science while addressing urgent health needs.
To learn more about FAST and its initiatives, please visit www.cureangelman.org.
Angelman Syndrome is characterized by the loss of function of the UBE3A gene, primarily inherited from the mother. Individuals with this condition face multiple challenges including developmental delays, motor difficulties, and speech impairments. Given the complexities surrounding the disorder, the implications of effective RNA-targeted therapies are profound; they promise not only to alleviate symptoms but also to enhance overall development and quality of life for affected individuals.
Dr. Arnold's project will harness the power of directed evolution—a technique she developed—to engineer enzymes that create new nucleoside analogs. These synthetic molecules have the potential to resist breakdown in the body, which is crucial for improving the efficacy of RNA therapeutics. The process is not merely academic; it represents a significant leap in practical applications that could lead to new therapies for Angelman Syndrome.
In this particular project, the aim is to produce nucleoside analogs that will effectively target the UBE3A antisense transcript (UBE3A-ATS). This approach has the potential not only to drive forward existing research but to provide a foundation for future treatments that might prove beneficial to patients. Dr. Arnold commented on the excitement of merging biochemistry and technological innovation, reflecting on the unprecedented opportunities these new building blocks bring for RNA therapeutics targeting Angelman Syndrome.
Despite their promise, nucleoside analogs present manufacturing challenges that have limited widespread use in the therapeutic landscape. However, by combining directed evolution and machine learning techniques, Dr. Arnold’s lab is aiming to overcome these obstacles to manufacture these critical molecules more efficiently. The first phase of this research will likely center around generating new therapeutic candidates that boast enhanced physical properties, ultimately leading to the discovery of more effective treatments.
FAST's initiative supports the second pillar of its Angelman syndrome drug development pipeline, concentrating on therapies that focus on the expression of the paternal UBE3A gene that remains dormant in patients. If this research yields promising candidates, experimental testing will be conducted with collaborators involved in the Angelman Syndrome research network, using AS neuronal cell lines and animal models.
Dr. Allyson Berent, Chief Science Officer of FAST, emphasized the importance of scientific progression in moving forward with Angelman Syndrome drug development. This grant facilitates collaboration with one of the foremost experts in the field, potentially expediting the transition from promising research to tangible therapies.
Supporting this endeavor is Maddie's Mission Foundation in partnership with the Shaw Family, a group dedicated to improving the lives of those with Angelman syndrome and other rare neurological disorders. Alana Newhouse, President of FAST, affirmed the significance of investment into research that blends top-tier scientific expertise with a focus on real-world applications. It is efforts like these that will not only create pathways for potential therapies today but will also ensure that future innovations are explored and utilized effectively.
The investment from FAST highlights its broader mission to fund the essential tools and research needed to transition from scientific opportunity to practical therapeutic solutions for individuals living with Angelman Syndrome. As the project progresses, there is a renewed hope for families affected by this condition, representing a promising avenue for advancing medical science while addressing urgent health needs.
To learn more about FAST and its initiatives, please visit www.cureangelman.org.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.